Steroids and injury to the developing brain: net harm or net benefit?

Area of Science:

• Neonatal Medicine
• Pediatric Endocrinology
• Developmental Neuroscience

Background:

• Glucocorticoids play a critical role in brain development, with both deficiency and excess causing harm.
• Premature infants often experience pulmonary dysfunction and may have relative adrenal insufficiency.
• Balancing the benefits and risks of glucocorticoid therapy in neonates is a significant clinical challenge.

Purpose of the Study:

• To evaluate the net benefit of early postnatal glucocorticoid therapy in premature infants.
• To identify specific patient populations, such as those with pulmonary dysfunction and adrenal insufficiency, who may benefit most.
• To guide clinical decision-making regarding steroid administration to optimize respiratory outcomes while minimizing neurological and systemic risks.

Main Methods:

• Review of accumulating evidence on postnatal glucocorticoid therapy in premature infants.
• Analysis of outcomes related to respiratory function, neurological risk, and systemic complications.
• Consideration of the timing of administration (shortly after the first week of life).

Main Results:

• Evidence suggests a net benefit of early postnatal glucocorticoid therapy in specific premature infant populations.
• Therapy appears particularly beneficial for infants with early, persistent pulmonary dysfunction and relative adrenal insufficiency.
• The approach aims to maximize respiratory improvement while minimizing neurological and systemic adverse effects.

Conclusions:

• Early postnatal glucocorticoid therapy can offer a net benefit to select premature infants.
• Clinical decisions must carefully weigh respiratory advantages against potential neurological risks.
• Ongoing clinical trials are essential to validate this therapeutic strategy and refine its application.